Skip to main content
Top
Published in: Endocrine 3/2013

01-12-2013 | Mini Review

Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature

Authors: Maria Alevizaki, Elena Kyratzoglou, Aristoteles Bamias, Marinella Tzanela, Meletios A. Dimopoulos, Katerina Saltiki

Published in: Endocrine | Issue 3/2013

Login to get access

Abstract

Medullary thyroid carcinoma (MTC) is a rare tumour which frequently occurs in the context of the multiple endocrine neoplasia syndromes, where it coexists with other usually benign tumours. The clinical picture varies and distant metastases are frequently present at diagnosis. Calcitonin levels are elevated in the presence of metastatic disease. Two MTC cases are presented, which had elevated postoperative calcitonin levels. Imaging revealed lung lesions which were originally attributed to metastatic disease from the MTC. However, at follow-up, these cases presented unusual features. The rapid increase in the lung lesions and the development of hypercalcaemia in the first patient suggested a second unrelated tumour. Biopsy of the lung lesion was compatible with lung adenocarcinoma. In the second patient, the appearance of a liver mass, although calcitonin levels remained stable, led to biopsy of the lesion: this was negative for calcitonin and compatible with metastatic lung adenocarcinoma. These MTC cases show that further malignancies may coexist with MTC and may obscure the clinical picture and influence the therapeutic decisions, especially in the case of metastatic disease. Features such as unusual imaging characteristics and the development of hypercalcemia, never encountered in MTC outside the MEN2 syndromes, as well as ‘disproportionately’ low calcitonin levels, incompatible with extensive metastatic disease, were the factors that led to further work-up. Both the cases subsequently proved to carry an unsuspected second malignancy. It is crucial to discriminate the metastatic lesion attributed to MTC from another coexisting primary malignancy, because different therapeutic strategies are needed for each setting.
Literature
2.
go back to reference E. Modigliani, R. Cohen, J.M. Campos, B. Conte-Devolx, B. Maes, A. Boneu, M. Schlumberger, J.C. Bigorgne, P. Dumontier, L. Leclerc, B. Corcuff, I. Guilhem, Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin. Endocrinol. (Oxf). 48(3), 265–273 (1998)PubMedCrossRef E. Modigliani, R. Cohen, J.M. Campos, B. Conte-Devolx, B. Maes, A. Boneu, M. Schlumberger, J.C. Bigorgne, P. Dumontier, L. Leclerc, B. Corcuff, I. Guilhem, Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin. Endocrinol. (Oxf). 48(3), 265–273 (1998)PubMedCrossRef
4.
go back to reference M. Alevizaki, K. Saltiki, G. Rentziou, A. Papathoma, L. Sarika, V. Vasileiou, E. Anastasiou, Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression. Eur. J. Endocrinol. 167(6), 799–808 (2012). doi:10.1530/EJE-12-0388 PubMedCrossRef M. Alevizaki, K. Saltiki, G. Rentziou, A. Papathoma, L. Sarika, V. Vasileiou, E. Anastasiou, Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression. Eur. J. Endocrinol. 167(6), 799–808 (2012). doi:10.​1530/​EJE-12-0388 PubMedCrossRef
5.
go back to reference R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, R.F. Gagel, H. Gharib, J.F. Moley, F. Pacini, M.D. Ringel, M. Schlumberger, S.A. Wells Jr, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6), 565–612 (2009). doi:10.1089/thy.2008.0403 PubMedCrossRef R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, R.F. Gagel, H. Gharib, J.F. Moley, F. Pacini, M.D. Ringel, M. Schlumberger, S.A. Wells Jr, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6), 565–612 (2009). doi:10.​1089/​thy.​2008.​0403 PubMedCrossRef
6.
go back to reference S. Hasani-Ranjbar, M.M. Amoli, Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome. Endocrine (2012). doi:10.1007/s12020-012-9610-6 S. Hasani-Ranjbar, M.M. Amoli, Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome. Endocrine (2012). doi:10.​1007/​s12020-012-9610-6
7.
go back to reference S. Mastroianno, M. Torlontano, A. Scillitani, L. D’Aloiso, A. Verrienti, N. Bonfitto, A. De Bonis, L. D’Agruma, L.A. Muscarella, V. Guarnieri, F. Dicembrino, M. Maranghi, C. Durante, S. Filetti, Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. Endocrine 40(3), 481–485 (2011). doi:10.1007/s12020-011-9501-2 PubMedCrossRef S. Mastroianno, M. Torlontano, A. Scillitani, L. D’Aloiso, A. Verrienti, N. Bonfitto, A. De Bonis, L. D’Agruma, L.A. Muscarella, V. Guarnieri, F. Dicembrino, M. Maranghi, C. Durante, S. Filetti, Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. Endocrine 40(3), 481–485 (2011). doi:10.​1007/​s12020-011-9501-2 PubMedCrossRef
8.
go back to reference W.G. Kim, G. Gong, E.Y. Kim, T.Y. Kim, S.J. Hong, W.B. Kim, Y.K. Shong, Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clin. Endocrinol. (Oxf). 72(2), 256–263 (2010). doi:10.1111/j.1365-2265.2009.03622.x PubMedCrossRef W.G. Kim, G. Gong, E.Y. Kim, T.Y. Kim, S.J. Hong, W.B. Kim, Y.K. Shong, Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clin. Endocrinol. (Oxf). 72(2), 256–263 (2010). doi:10.​1111/​j.​1365-2265.​2009.​03622.​x PubMedCrossRef
9.
go back to reference R.L. Wong, H.S. Kazaure, S.A. Roman, J.A. Sosa, Simultaneous medullary and differentiated thyroid cancer: a population-level analysis of an increasingly common entity. Ann. Surg. Oncol. 19(8), 2635–2642 (2012). doi:10.1245/s10434-012-2357-8 PubMedCrossRef R.L. Wong, H.S. Kazaure, S.A. Roman, J.A. Sosa, Simultaneous medullary and differentiated thyroid cancer: a population-level analysis of an increasingly common entity. Ann. Surg. Oncol. 19(8), 2635–2642 (2012). doi:10.​1245/​s10434-012-2357-8 PubMedCrossRef
11.
go back to reference S. Rossi, L. Fugazzola, L. De Pasquale, P. Braidotti, V. Cirello, P. Beck-Peccoz, S. Bosari, A. Bastagli, Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr. Relat. Cancer 12(2), 281–289 (2005). doi:10.1677/erc.1.00901 PubMedCrossRef S. Rossi, L. Fugazzola, L. De Pasquale, P. Braidotti, V. Cirello, P. Beck-Peccoz, S. Bosari, A. Bastagli, Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr. Relat. Cancer 12(2), 281–289 (2005). doi:10.​1677/​erc.​1.​00901 PubMedCrossRef
12.
go back to reference R.P. Biscolla, C. Ugolini, M. Sculli, V. Bottici, M.G. Castagna, C. Romei, B. Cosci, E. Molinaro, P. Faviana, F. Basolo, P. Miccoli, F. Pacini, A. Pinchera, R. Elisei, Medullary and papillary tumours are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 14(11), 946–952 (2004). doi:10.1089/thy.2004.14.946 PubMedCrossRef R.P. Biscolla, C. Ugolini, M. Sculli, V. Bottici, M.G. Castagna, C. Romei, B. Cosci, E. Molinaro, P. Faviana, F. Basolo, P. Miccoli, F. Pacini, A. Pinchera, R. Elisei, Medullary and papillary tumours are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 14(11), 946–952 (2004). doi:10.​1089/​thy.​2004.​14.​946 PubMedCrossRef
13.
go back to reference F. Bertagna, G. Treglia, A. Piccardo, E. Giovannini, G. Bosio, G. Biasiotto, E.K. Bahij, R. Maroldi, R. Giubbini, F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine (2012). doi:10.1007/s12020-012-9837-2 PubMed F. Bertagna, G. Treglia, A. Piccardo, E. Giovannini, G. Bosio, G. Biasiotto, E.K. Bahij, R. Maroldi, R. Giubbini, F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine (2012). doi:10.​1007/​s12020-012-9837-2 PubMed
14.
go back to reference A. Bocian, J. Kopczynski, P. Rieske, S. Piaskowski, J. Sluszniak, D. Kupnicka, S. Gozdz, A. Kowalska, J. Sygut, Simultaneous occurrence of medullary and papillary carcinomas of the thyroid gland with metastases of papillary carcinoma to the cervical lymph nodes and the coinciding small B-cell lymphocytic lymphoma of the lymph nodes: a case report. Pol. J. Pathol. 55(3), 23–30 (2004)PubMed A. Bocian, J. Kopczynski, P. Rieske, S. Piaskowski, J. Sluszniak, D. Kupnicka, S. Gozdz, A. Kowalska, J. Sygut, Simultaneous occurrence of medullary and papillary carcinomas of the thyroid gland with metastases of papillary carcinoma to the cervical lymph nodes and the coinciding small B-cell lymphocytic lymphoma of the lymph nodes: a case report. Pol. J. Pathol. 55(3), 23–30 (2004)PubMed
15.
go back to reference M.F. Saad, N.G. Ordonez, R.K. Rashid, J.J. Guido, C.S. Hill Jr, R.C. Hickey, N.A. Samaan, Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6), 319–342 (1984) M.F. Saad, N.G. Ordonez, R.K. Rashid, J.J. Guido, C.S. Hill Jr, R.C. Hickey, N.A. Samaan, Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6), 319–342 (1984)
16.
go back to reference T. Papajik, M. Myslivecek, Z. Sedova, E. Buriankova, V. Prochazka, L. Raida, Z. Kubova, C. Neoral, D. Starostka, P. Mikula, B. Melichar, L. Kucerova, M. Tichy, K. Indrak, Synchronous second primary neoplasms detected by initial staging F-18 FDG PET/CT examination in patients with non-Hodgkin lymphoma. Clin. Nucl. Med. 36(7), 509–512 (2011). doi:10.1097/RLU.0b013e318217541d PubMedCrossRef T. Papajik, M. Myslivecek, Z. Sedova, E. Buriankova, V. Prochazka, L. Raida, Z. Kubova, C. Neoral, D. Starostka, P. Mikula, B. Melichar, L. Kucerova, M. Tichy, K. Indrak, Synchronous second primary neoplasms detected by initial staging F-18 FDG PET/CT examination in patients with non-Hodgkin lymphoma. Clin. Nucl. Med. 36(7), 509–512 (2011). doi:10.​1097/​RLU.​0b013e318217541d​ PubMedCrossRef
17.
go back to reference L.B. Travis, C.S. Rabkin, L.M. Brown, J.M. Allan, B.P. Alter, C.B. Ambrosone, C.B. Begg, N. Caporaso, S. Chanock, A. DeMichele, W.D. Figg, M.K. Gospodarowicz, E.J. Hall, M. Hisada, P. Inskip, R. Kleinerman, J.B. Little, D. Malkin, A.K. Ng, K. Offit, C.H. Pui, L.L. Robison, N. Rothman, P.G. Shields, L. Strong, T. Taniguchi, M.A. Tucker, M.H. Greene, Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 98(1), 15–25 (2006). doi:10.1093/jnci/djj001 PubMedCrossRef L.B. Travis, C.S. Rabkin, L.M. Brown, J.M. Allan, B.P. Alter, C.B. Ambrosone, C.B. Begg, N. Caporaso, S. Chanock, A. DeMichele, W.D. Figg, M.K. Gospodarowicz, E.J. Hall, M. Hisada, P. Inskip, R. Kleinerman, J.B. Little, D. Malkin, A.K. Ng, K. Offit, C.H. Pui, L.L. Robison, N. Rothman, P.G. Shields, L. Strong, T. Taniguchi, M.A. Tucker, M.H. Greene, Cancer survivorship: genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 98(1), 15–25 (2006). doi:10.​1093/​jnci/​djj001 PubMedCrossRef
18.
go back to reference S.A. Wells Jr, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30(2), 134–141 (2012). doi:10.1200/JCO.2011.35.5040 PubMedCrossRef S.A. Wells Jr, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30(2), 134–141 (2012). doi:10.​1200/​JCO.​2011.​35.​5040 PubMedCrossRef
20.
22.
go back to reference P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, K. Hemminki, Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78–85 (2000). doi:10.1056/NEJM200007133430201 PubMedCrossRef P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, K. Hemminki, Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78–85 (2000). doi:10.​1056/​NEJM200007133430​201 PubMedCrossRef
23.
go back to reference R.F. Gagel, M.F. Robinson, D.T. Donovan, B.R. Alford, Clinical review 44: medullary thyroid carcinoma: recent progress. J. Clin. Endocrinol. Metab. 76(4), 809–814 (1993)PubMedCrossRef R.F. Gagel, M.F. Robinson, D.T. Donovan, B.R. Alford, Clinical review 44: medullary thyroid carcinoma: recent progress. J. Clin. Endocrinol. Metab. 76(4), 809–814 (1993)PubMedCrossRef
27.
go back to reference A.L. Shifrin, J.B. Ogilvie, M.T. Stang, A.M. Fay, Y.H. Kuo, T. Matulewicz, C.Z. Xenachis, J.J. Vernick, Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804 M proto-oncogene mutation. Surgery 148(6), 1274–1280 (2010). doi:10.1016/j.surg.2010.09.004. discussion 1280–1271PubMedCrossRef A.L. Shifrin, J.B. Ogilvie, M.T. Stang, A.M. Fay, Y.H. Kuo, T. Matulewicz, C.Z. Xenachis, J.J. Vernick, Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804 M proto-oncogene mutation. Surgery 148(6), 1274–1280 (2010). doi:10.​1016/​j.​surg.​2010.​09.​004. discussion 1280–1271PubMedCrossRef
28.
go back to reference G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80–87 (2012). doi:10.1007/s12020-012-9631-1 PubMedCrossRef G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80–87 (2012). doi:10.​1007/​s12020-012-9631-1 PubMedCrossRef
29.
go back to reference G. Treglia, M.F. Villani, A. Giordano, V. Rufini, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42(3), 535–545 (2012). doi:10.1007/s12020-012-9671-6 PubMedCrossRef G. Treglia, M.F. Villani, A. Giordano, V. Rufini, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42(3), 535–545 (2012). doi:10.​1007/​s12020-012-9671-6 PubMedCrossRef
31.
go back to reference M. Zabel, J. Grzeszkowiak, Characterisation of thyroid medullary carcinoma TT cell line. Histol. Histopathol. 12(1), 283–289 (1997)PubMed M. Zabel, J. Grzeszkowiak, Characterisation of thyroid medullary carcinoma TT cell line. Histol. Histopathol. 12(1), 283–289 (1997)PubMed
32.
go back to reference A. Machens, K. Lorenz, H. Dralle, Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. J. Clin. Endocrinol. Metab. 98(2), E336–E345 (2013). doi:10.1210/jc.2012-3192 PubMedCrossRef A. Machens, K. Lorenz, H. Dralle, Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. J. Clin. Endocrinol. Metab. 98(2), E336–E345 (2013). doi:10.​1210/​jc.​2012-3192 PubMedCrossRef
33.
go back to reference D.V. Alapat, K.B. Ain, D.A. Sloan, K.G. Monaghan, R.G. Karabakhtsian, Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine 39(2), 148–152 (2011). doi:10.1007/s12020-010-9433-2 PubMedCrossRef D.V. Alapat, K.B. Ain, D.A. Sloan, K.G. Monaghan, R.G. Karabakhtsian, Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine 39(2), 148–152 (2011). doi:10.​1007/​s12020-010-9433-2 PubMedCrossRef
34.
go back to reference D.R. Clarke, L.A. Smallman, P.H. Rhys-Evans, Triple primary malignant neoplasms in the head and neck. J. R. Soc. Med. 79(11), 676–677 (1986)PubMed D.R. Clarke, L.A. Smallman, P.H. Rhys-Evans, Triple primary malignant neoplasms in the head and neck. J. R. Soc. Med. 79(11), 676–677 (1986)PubMed
35.
go back to reference T.K. Lee, R.T. Myers, M. Scharyj, R.B. Marshall, Multiple primary malignant tumours (MPMT): study of 68 autopsy cases (1963–1980). J. Am. Geriatr. Soc. 30(12), 744–753 (1982)PubMed T.K. Lee, R.T. Myers, M. Scharyj, R.B. Marshall, Multiple primary malignant tumours (MPMT): study of 68 autopsy cases (1963–1980). J. Am. Geriatr. Soc. 30(12), 744–753 (1982)PubMed
36.
go back to reference T.C. Sandeep, M.W. Strachan, R.M. Reynolds, D.H. Brewster, G. Scelo, E. Pukkala, K. Hemminki, A. Anderson, E. Tracey, S. Friis, M.L. McBride, C. Kee-Seng, V. Pompe-Kirn, E.V. Kliewer, J.M. Tonita, J.G. Jonasson, C. Martos, P. Boffetta, P. Brennan, Second primary cancers in thyroid cancer patients: a multinational record linkage study. J. Clin. Endocrinol. Metab. 91(5), 1819–1825 (2006). doi:10.1210/jc.2005-2009 PubMedCrossRef T.C. Sandeep, M.W. Strachan, R.M. Reynolds, D.H. Brewster, G. Scelo, E. Pukkala, K. Hemminki, A. Anderson, E. Tracey, S. Friis, M.L. McBride, C. Kee-Seng, V. Pompe-Kirn, E.V. Kliewer, J.M. Tonita, J.G. Jonasson, C. Martos, P. Boffetta, P. Brennan, Second primary cancers in thyroid cancer patients: a multinational record linkage study. J. Clin. Endocrinol. Metab. 91(5), 1819–1825 (2006). doi:10.​1210/​jc.​2005-2009 PubMedCrossRef
37.
go back to reference R.F. Gagel, A.H. Tashjian Jr, T. Cummings, N. Papathanasopoulos, M.M. Kaplan, R.A. DeLellis, H.J. Wolfe, S. Reichlin, The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N. Engl. J. Med. 318(8), 478–484 (1988). doi:10.1056/NEJM198802253180804 PubMedCrossRef R.F. Gagel, A.H. Tashjian Jr, T. Cummings, N. Papathanasopoulos, M.M. Kaplan, R.A. DeLellis, H.J. Wolfe, S. Reichlin, The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N. Engl. J. Med. 318(8), 478–484 (1988). doi:10.​1056/​NEJM198802253180​804 PubMedCrossRef
38.
go back to reference M. Alevizaki, P. Papapetrou, P. Georgouli, C.C. Alevizaki, H. Papadodima, A. Souvatzoglou, D. Koutras, Increased incidence of medullary carcinoma of the thyroid in rural regions in Greece. J. Endocrinol. Investig. 18(3), 220–223 (1995) M. Alevizaki, P. Papapetrou, P. Georgouli, C.C. Alevizaki, H. Papadodima, A. Souvatzoglou, D. Koutras, Increased incidence of medullary carcinoma of the thyroid in rural regions in Greece. J. Endocrinol. Investig. 18(3), 220–223 (1995)
Metadata
Title
Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature
Authors
Maria Alevizaki
Elena Kyratzoglou
Aristoteles Bamias
Marinella Tzanela
Meletios A. Dimopoulos
Katerina Saltiki
Publication date
01-12-2013
Publisher
Springer US
Published in
Endocrine / Issue 3/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-9961-7

Other articles of this Issue 3/2013

Endocrine 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine